0000000000388956

AUTHOR

Giuseppe Avvisati

showing 5 related works from this author

Incidence of venous thromboembolism and use of anticoagulation in hematological malignancies: Critical review of the literature.

2018

Venous Thromboembolism (VTE) frequently complicates the course of hematologic malignancies (HM) and its incidence is similar to that observed in high-risk solid tumors. Despite that, pharmacologic prophylaxis and treatment of VTE in patients with HM is challenging, mainly because a severe thrombocytopenia frequently complicates the course of treatments or may be present since diagnosis, thus increasing the risk of bleeding. Therefore, in this setting, safe and effective methods of VTE prophylaxis and treatment have not been well defined and hematologists generally refer to guidelines produced for cancer patients that give indications on anticoagulation in patients with thrombocytopenia. In …

medicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentvenous thromboembolismLow molecular weight heparinHemorrhage030204 cardiovascular system & hematologyVte prophylaxis03 medical and health sciences0302 clinical medicineAntithromboticmedicineAnimalsHumanscardiovascular diseasesIntensive care medicineChemotherapybusiness.industryIncidence (epidemiology)IncidenceCancerAnticoagulantsHematologyVenous ThromboembolismHeparin Low-Molecular-Weightmedicine.diseaseThrombocytopeniaSevere thrombocytopeniaOncology030220 oncology & carcinogenesisHematologic NeoplasmsbusinessVenous thromboembolismCritical reviews in oncology/hematology
researchProduct

Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study.

2018

© 2018 The Authors.

MaleCancer ResearchBoronic Acid[SDV]Life Sciences [q-bio]bortezomib ; global ; observational study ; routine practice ; stem cell transplantationSalvage therapyPractice PatternsDexamethasoneBortezomibRoutine practice0302 clinical medicineBortezomib; Global; Observational study; Routine practice; Stem cell transplantationhemic and lymphatic diseasesObservational studyAntineoplastic Combined Chemotherapy Protocols80 and overProspective StudiesPractice Patterns Physicians'Prospective cohort studyLenalidomideComputingMilieux_MISCELLANEOUSMultiple myelomaAged 80 and overBortezomibStem cell transplantationGlobalHematologyMiddle AgedBoronic Acids3. Good healthThalidomideSurvival RateTreatment OutcomeLocalOncology030220 oncology & carcinogenesisBortezomib; Global; Observational study; Routine practice; Stem cell transplantation; Hematology; Oncology; Cancer ResearchFemaleMultiple MyelomaBortezomib; Global; Observational study; Routine practice; Stem cell transplantation; Adult; Aged; Aged 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence Local; Prospective Studies; Survival Rate; Thalidomide; Treatment Outcome; Practice Patterns Physicians'; Salvage Therapymedicine.drugHumanAdultmedicine.medical_specialty/NOFollow-Up Studie03 medical and health sciencesInternal medicinemedicineHumansSurvival rateLenalidomideAgedSalvage TherapyPhysicians'Antineoplastic Combined Chemotherapy Protocolbusiness.industrySettore MED/15medicine.diseaseTransplantationThalidomideSettore MED/15 - MALATTIE DEL SANGUEProspective StudieNeoplasm RecurrenceNeoplasm Recurrence Localbusiness030215 immunologyFollow-Up StudiesClinical lymphoma, myelomaleukemia
researchProduct

Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet

2019

Abstract Since the comprehensive recommendations for the management of acute promyelocytic leukemia (APL) reported in 2009, several studies have provided important insights, particularly regarding the role of arsenic trioxide (ATO) in frontline therapy. Ten years later, a European LeukemiaNet expert panel has reviewed the recent advances in the management of APL in both frontline and relapse settings in order to develop updated evidence- and expert opinion–based recommendations on the management of this disease. Together with providing current indications on genetic diagnosis, modern risk-adapted frontline therapy, and salvage treatment, the review contains specific recommendations for the …

Acute promyelocytic leukemiamedicine.medical_specialtymedicine.medical_treatmentImmunologyMEDLINETretinoinDiseaseHemorrhagic DisordersBiochemistryHemorrhagic disorderEuropean LeukemiaNetArsenic TrioxideLeukemia Promyelocytic AcutePregnancyRecurrenceHumansMedicineDisease management (health)Intensive care medicineSpecial ReportNeoadjuvant therapyAPL Differentiation SyndromeAgedbusiness.industryDisease ManagementCell BiologyHematologymedicine.diseasePractice Guidelines as TopicFemalebusinessBlood
researchProduct

Zoledronic acid induces a significant decrease of circulating endothelial cells and circulating endothelial precursor cells in the early prostate can…

2012

<b><i>Purpose:</i></b> Published data demonstrated that zoledronic acid (ZOL) exhibits antiangiogenetic effects. A promising tool for monitoring antiangiogenic therapies is the measurement of circulating endothelial cells (CECs) and circulating endothelial precursor cells (CEPs) in the peripheral blood of patients. Our aim was to investigate the effects of ZOL on levels of CECs and CEPs in localized prostate cancer. <b><i>Methods:</i></b> Ten consecutive patients with a histologic diagnosis of low-risk prostate adenocarcinoma were enrolled and received an intravenous infusion of ZOL at baseline (T0), 28 days (T28) and 56 days (T56). Blood samp…

Malemedicine.medical_specialtyPathologyCancer ResearchBone Density Conservation AgentAngiogenesismedicine.medical_treatmentUrologyAngiogenesis InhibitorsAngiogenesis; Circulating endothelial cells; Circulating endothelial precursor cells; Prostate cancer; Zoledronic acid; Aged; Angiogenesis Inhibitors; Bone Density Conservation Agents; Cell Movement; Diphosphonates; Endothelial Cells; Humans; Imidazoles; Male; Middle Aged; Neoadjuvant Therapy; Prostatic Neoplasms; Stem Cells; Medicine (all); Oncology; Cancer ResearchFlow cytometryProstate cancerCirculating endothelial cellCell MovementStem CellPrecursor cellMedicineHumansImidazoleNeoadjuvant therapyZoledronic acidAgedEndothelial CellProstate cancermedicine.diagnostic_testBone Density Conservation AgentsDiphosphonatesbusiness.industryStem CellsMedicine (all)ImidazolesEndothelial CellsProstatic NeoplasmsGeneral MedicineMiddle Agedmedicine.diseasePeripheral bloodNeoadjuvant TherapyAngiogenesiZoledronic acidDiphosphonateOncologyCirculating endothelial precursor cellProstatic NeoplasmStem cellbusinessmedicine.drugAngiogenesis InhibitorHuman
researchProduct

Improved Outcome with ATRA-Arsenic Trioxide Compared to ATRA-Chemotherapy in Non-High Risk Acute Promyelocytic Leukemia - Updated Results of the Ital…

2014

Abstract Background: We recently showed that the combination of ATRA and arsenic trioxide (ATO) is at least not inferior and possibly superior to standard ATRA and chemotherapy (CHT) in the front-line management of low/intermediate risk APL (Italian-German APL 0406 trial; Lo-Coco et al., NEJM 2013). We report herein on the extended and final series of 276 patients (162 were in the previous report) with the last case being enrolled into the study in January 2013. Methods: The APL0406 study was a prospective, open-label, randomized intergroup trial conducted by the Italian GIMEMA and the German SAL and AMLSG study groups. Eligible patients were adults aged 18-<71 years with newly diagnosed…

Acute promyelocytic leukemiaPediatricsmedicine.medical_specialtyChemotherapyAnthracyclinebusiness.industrymedicine.medical_treatmentImmunologyCell BiologyHematologyOff-label usemedicine.diseaseBiochemistrychemistry.chemical_compoundchemistryInternal medicineCohortmedicineIdarubicinCumulative incidenceArsenic trioxidebusinessmedicine.drug
researchProduct